Calithera Biosciences to Present New Data on Two Oncology Programs at ESMO Congress 2019
September 03 2019 - 9:00AM
Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage
biotechnology company focused on discovering and developing novel
small molecule drugs for the treatment of cancer and other
life-threatening diseases, today announced that new data from two
oncology programs have been selected for oral presentations at the
European Society for Medical Oncology (ESMO) 2019 Congress to be
held September 27-October 1, in Barcelona, Spain.
The late-breaking abstract (#LBA54) titled, “ENTRATA:
Randomized, double-blind, phase 2 study of telaglenastat
(CB-839) + everolimus vs. placebo + everolimus in patients
with advanced/metastatic renal cell carcinoma (RCC),” has been
selected for oral presentation as part of a session titled,
“Proffered Paper 1-Genitourinary tumors, non-prostate” on September
28, 2019, at 8:30 a.m. CET in Barcelona Auditorium (Hall 2). The
oral presentation will be led by Chung-Han Lee of the Memorial
Sloan Kettering Cancer Center, New York, NY.
The oral abstract (#440O) titled, “Phase 1 study of the arginase
inhibitor INCB001158 (1158) alone and in combination with
pembrolizumab in patients with advanced/metastatic solid tumors,”
has been accepted for oral presentation as part of a session
titled, “Proffered Paper – Developmental therapeutics,” on
September 29, 2019, at 4:30 p.m. CET in the Malaga Auditorium (Hall
5). The oral presentation will be led by Aung Naing, M.D., FACP,
Associate Professor, Department of Investigational Cancer
Therapeutics, Division of Cancer Medicine, The University of Texas
MD Anderson Cancer Center, Houston, TX.
“We look forward to presenting data from the ENTRATA trial, for
which positive topline results were announced earlier this year, as
well as new data from our clinical program partnered with Incyte
that is evaluating the arginase inhibitor INCB001158 in solid
tumors,” said Susan Molineaux, Ph.D., president and chief executive
officer at Calithera. “We remain committed to advancing our robust
pipeline, including our lead compound telaglenastat for which the
registrational CANTATA trial in RCC is underway and expected to
readout in the second half of 2020.”
About Telaglenastat
Telaglenastat is an investigational first-in-class, novel
glutaminase inhibitor specifically designed to block glutamine
consumption in tumor cells. RCC tumors commonly exhibit metabolic
alterations that increase their dependence on glutamine. In
preclinical studies, telaglenastat produced synergistic antitumor
effects when used in combination with standard-of-care RCC
therapies. The randomized Phase 2 ENTRATA trial of telaglenastat
plus everolimus versus everolimus plus placebo met its primary
endpoint of improving progression free survival, demonstrating
proof of concept for telaglenastat in patients with advanced RCC.
The ongoing CANTATA trial is a global, randomized, double-blind
trial designed to evaluate the safety and efficacy of telaglenastat
plus cabozantinib versus placebo plus cabozantinib in patients with
advanced or metastatic RCC.
About INCB001158 (CB-1158)
INCB001158 (CB-1158) is an investigational first-in-class, novel
small molecule arginase inhibitor. Arginase is an enzyme that
suppresses the immune-mediated destruction of tumors by depleting
levels of a key amino acid, L-arginine, from the tumor
microenvironment. A number of cell types in the tumor
microenvironment, including myeloid-derived suppressor cells,
macrophages, and neutrophils, can secrete arginase. L-arginine
deprivation can act via nutrient sensor pathways to exert several
suppressive effects on T-cell function, inhibiting proliferation,
decreasing cytokine production, and diminishing expression of the
T-cell receptor CD3ζ chain. Arginase activity may thus impair
T-cell mediated anti-tumor responses. INCB001158 is being developed
in a global collaboration with Incyte Corporation.
About Calithera
Calithera Biosciences is a clinical-stage biopharmaceutical
company pioneering the discovery and development of targeted
therapies that disrupt cellular metabolic pathways to
preferentially block tumor cells and enhance immune-cell activity.
Driven by a commitment to rigorous science and a passion for
improving the lives of people impacted by cancer and other
life-threatening diseases, Calithera is advancing a pipeline of
first-in-clinic, oral therapeutics to meaningfully expand treatment
options available to patients. Calithera is headquartered in South
San Francisco, California. For more information about Calithera,
please visit www.calithera.com.
Forward Looking Statements
Statements contained in this press release regarding matters
that are not historical facts are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act
of 1995. Words such as "may," "will," "expect," "anticipate,"
"estimate," "intend," "poised" and similar expressions (as well as
other words or expressions referencing future events, conditions,
or circumstances) are intended to identify forward-looking
statements. These statements include those related to the safety,
tolerability and efficacy of Calithera’s product candidates, the
overall advancement of Calithera’s product candidates in clinical
trials, the unmet need in the treatment of patients with advanced
disease, and Calithera’s plans to continue development of its
product candidates. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. The
product candidates that Calithera develops may not progress through
clinical development or receive required regulatory approvals
within expected timelines or at all. In addition, clinical trials
may not confirm any safety, potency or other product
characteristics described or assumed in this press release. Such
product candidates may not be beneficial to patients or
successfully commercialized. The failure to meet expectations with
respect to any of the foregoing matters may have a negative effect
on Calithera's stock price. Additional information concerning these
and other risk factors affecting Calithera's business can be found
in Calithera's most recent Quarterly Report on Form 10-Q filed with
the Securities and Exchange Commission, and other periodic filings
with the Securities and Exchange Commission at www.sec.gov. These
forward-looking statements are not guarantees of future performance
and speak only as of the date hereof, and, except as required by
law, Calithera disclaims any obligation to update these
forward-looking statements to reflect future events or
circumstances.
SOURCE: Calithera Biosciences,
Incorporated
CONTACT:
Jennifer McNealey ir@Calithera.com650-870-1071
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Calithera Biosciences (NASDAQ:CALA)
Historical Stock Chart
From Apr 2023 to Apr 2024